Supplementary materials Tanaka et al.

This is the supplementary data for the study to elucidate how anti-interleukin 6 receptor blockade by MR16-1 ameliorate salt-induced cardiac inflammation and fibrosis in uremic mouse

Clinical characteristics of 80 patients with relapse and non-relapse.

(DOCX)</p

Comparison of outcome data between RLV and non-RLV groups.

Comparison of outcome data between RLV and non-RLV groups.</p

Predictors of the first relapse.

(DOCX)</p

Immunosuppressive treatment during the observation period.

Immunosuppressive treatment during the observation period.</p

Flow diagram of patient selection.

AAV, antineutrophil cytoplasmic autoantibody–associated vasculitis; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RLV, renal-limited vasculitis.</p

Clinical characteristics of 69 patients who underwent renal biopsy compared on the basis of histologic classification.

(DOCX)</p

Univariate analysis in binary logistic regression to determine the predictors of relapse.

(DOCX)</p

Clinical characteristics of 80 patients in RLV and non-RLV groups who had achieved remission at 6 months.

Clinical characteristics of 80 patients in RLV and non-RLV groups who had achieved remission at 6 months.</p

Anonymized data set.

(XLSX)</p